Caplin Point Laboratories
CAPLIPOINT · Pharma > Pharmaceuticals & Drugs · Chairman: C C Paarthipan · MD: Sridhar Ganesan · Listing date: June 23, 2014 · Employees: 1675 · Chennai · http://www.caplinpoint.net

Stock Price vs Company Growth
1d
2.0%
1w
6.6%
1m
8.0%
3m
11.4%
6m
20.0%
1y
15.1%
5y
30.0%
10y
25.4%
all
40.0%

Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price

₹ 1,705 2.0%
1,672
1,990
Company Overview

Sales
2,089 Cr
Growth: 11.3%
Profit after Tax
614 Cr
Growth: 4.2%
Mid Cap
12,960 Cr
P/E: 21.6x
Industry P/E: 29.7x
Fundamentals

Sales (Cr) ₹ 2,089
Growth 11.3%
EBITDA 34.7%
P/S 6.3x
Dividend 0.3%
P/E 21.6x
Book Value ₹ 437
PEG Ratio 1.9x
ROE 19.9%
P/B 4.0x
Shareholding Pattern

Institutions
Promoters
P Vijayalakhsmi
23.64 %
Paarthipan C C
18.73 %
Ashok Gorkey Partheeban
11.96 %
Partheeban Vivek Siddarth
11.9 %
May India Property Private Limited
2.8 %
Others
Iepf
2.46 %
Visalatchi
2.22 %
Suresh Kumar Agarwal
1.32 %
Ashish Kacholia
1.16 %
Llp
0.7 %
Increase    Decrease    No change
Company Profile Detailed

Caplin Point is the mid-sized company in India’s pharmaceutical sector to be engaged in the manufacture of APIs, finished formulations, research & development, clinical research, frontend generic presence in Latin America, brand marketing in Francophone Africa and an USFDA approved injectable facility.
Investors (50)
Followers (28)